Cohort A: Patient with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion treated with amivantamab-platimum based chemotherapy via an early access program in first line setting.
Cohort B: Patient with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 19 or 21 treated with amivantamab-platimum based chemotherapy post osimertinib (with or without chemotherapy) via an early access program.
Patient covered by the French National Health Insurance system or by an approved third-party payer
Patient who does not object to the collection of their personal data for research purposes (an information sheet will be provided to all living participants; for deceased participants, documented non-opposition in the medical record is not required)
You may not be if
Patient placed under legal guardianship or subject to a protective legal measure
Patient who explicitly refuses the collection or use of their personal data for research purposes
Patient not enrolled, managed, or followed at the investigating site by a qualified site investigator